Clinical Trial Update: Instylla HES Hypervascular Tumor Pivotal Study [NA]

View source ↗

Summary

Update indicates the pivotal trial of Instylla's HES for hypervascular tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypervascular Tumors

Drugs mentioned

• Instylla HES

Snippet

Sponsor: Instylla, Inc. | Conditions: Hypervascular Tumors | NA | Status: COMPLETED